GeoVax Extends Research Collaborations on Zika Vaccine
Wednesday, March 30, 2016
Posted by: Angela King
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced that it has entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine.
On February 3, 2016, GeoVax announced that it had begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform, and that it had entered into a collaborative relationship with researchers at the University of Georgia to speed development of the vaccine. The Research Collaboration Agreement between GeoVax and the CDC should further broaden and accelerate the company's Zika vaccine development through access to Zika virus antibodies available at the CDC and testing of vaccine candidates by the CDC in appropriate animal models.
Robert McNally, PhD, GeoVax's President and CEO, commented, "We are pleased to have the support of multiple collaborators in our efforts to rapidly develop an efficacious vaccine to prevent Zika virus infection. Together with our own scientific staff, we have assembled a world-class team, with expertise in flavivirus vaccine development, in our attempt to develop a vaccine solution to this growing threat to world health."
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Source. Pharm Pro. http://www.pharmpro.com/news/2016/03/geovax-extends-research-collaborations-zika-vaccine